A Pilot Study on Continuous Infusion of 4% Albumin in Critically Ill Patients: Impact on Nosocomial Infection via a Reduction Mechanism for Oxidized Substrates.

Date publication

septembre 2019

Journal

Critical care explorations

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MEYER Nicolas , Pr SCHAAF Pierre

Tous les auteurs :
Schneider F, Dureau AF, Hellé S, Betscha C, Senger B, Cremel G, Boulmedais F, Strub JM, Corti A, Meyer N, Guillot M, Schaaf P, Metz-Boutigue MH

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32166286

Résumé

Care-related infections affect up to 11% of ICU patients. Running therapeutic albumin is sometimes associated to less infection: whether a specific method of its infusion is of any interest to modulate innate defense is unknown. Our objectives were: 1) to test whether the method for albumin infusion is important to prevent care-related infections and 2) to analyze in vitro the antioxidative role of albumin on host defense proteins during shock (using vasostatin-I as an example).

Mots clés

antimicrobial peptides, chromogranin A, critical care, nosocomial infections, protein-protein interaction, therapeutic albumin

Référence

Crit Care Explor. 2019 Sep;1(9):e0044